Literature DB >> 24815451

Social support and quality of life in Turkish patients with gynecologic cancer.

Evsen Nazik1, Funda Ozdemir, Selen Soydan.   

Abstract

The aim of this study was to determine the level of social support and quality of life in Turkish patients with gynecologic cancer using a cross-sectional survey design. A total of 108 patients admitted to the gynecologic oncology clinic at a university hospital from September 2011 to January 2012 were included. Data were collected using patient information forms, the Multidimensional Scale of Perceived Social Support (MSPSS) and The Quality of Life-Cancer Survivors Instrument (QOL-CS). Average age was 54.5±10.8 years and it was determined that 65.7% of patients had ovarian cancer and 19.4% had cervical cancer. The total QOL-CS mean score was 5.59±1.10. Average score of total MSPSS was found to be 69.7±14.64. Comparing socio-demographic and clinical characteristics of patients and average scores of QOL-CS and MSPSS, it was found that there was not a statisticaly significant corelation (p>0.05). Statistically significant relation was found between the average scores of QOL-CS and MSPSS. These results showed that quality of life was moderate and perceived social support was high in Turkish patients with gynecologic cancer.

Entities:  

Mesh:

Year:  2014        PMID: 24815451     DOI: 10.7314/apjcp.2014.15.7.3081

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  2 in total

Review 1.  Quality of Life in Thyroid Cancer is Similar to That of Other Cancers with Worse Survival.

Authors:  Megan K Applewhite; Benjamin C James; Sharone P Kaplan; Peter Angelos; Edwin L Kaplan; Raymon H Grogan; Briseis Aschebrook-Kilfoy
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

2.  Impact of caregivers' negative response to cancer on long-term survivors' quality of life.

Authors:  Alicia L Best; Rujuta Shukla; Abdullahi Musa Adamu; Dinorah Martinez Tyson; Kevin D Stein; Kassandra I Alcaraz
Journal:  Support Care Cancer       Date:  2020-05-20       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.